TRIUMPH-1 extension data: what happens after the trial stops
A design note rather than a result: what the comparator was, and what that permits you to conclude.
TheCompound Journal
Reporting on incretins, compounding & the peptide supply chain
Page 6 of 68 of this archive, newest first.
A design note rather than a result: what the comparator was, and what that permits you to conclude.
The evidence base is thin and the document says so, which is to its credit.
Every time a vial changes, the conversion must be recalculated. Carrying forward a unit count from the last vial is the single most reliable way to give the wrong dose.
The condition on arrival is recorded by some services and not others, and it is one of the more informative lines in a report.
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
Efficacy was never the question in this appraisal. Duration of treatment was.
The route did not close because of a rule about peptides.
Chromatographic software does not integrate every fluctuation in the baseline. It applies a threshold, and the threshold changes the reported purity by amounts that matter…
The published ladder exists because a protocol needed a single number. Practice has never followed it exactly, and the regulatory file never assumed it would.
A design note rather than a result: what the comparator was, and what that permits you to conclude.
Efficacy was never the question in this appraisal. Duration of treatment was.
A proper account of an operation that existed, and of what closing it cost.
The document is four pages. Three of them are about dates.
The commonest real-world strategy in this drug class is the least studied one.
The Journal submitted split samples from single lots to three assay services, under names unconnected to this publication, and published each method alongside each result.
A flag is a probability statement about a population. It is not a statement about the person holding the printout.
Follow the resin, not the catalogue.
The result is unremarkable. What the report states alongside it is not.
The observation that closes a facility is rarely the dramatic one.
The evidence base is thin and the document says so, which is to its credit.
Every degradation pathway accelerates by orders of magnitude on reconstitution, because the solvent that lyophilisation removed is the reagent most of them need.
The document is four pages. Three of them are about dates.
Follow the resin, not the catalogue.
A reminder that a purity figure is the output of a method, and that methods differ.
The evidence base here is the insulin injection-technique literature, which is large and transfers well on tissue questions.
The convention — resume lower, re-escalate — is not caution. It follows directly from the elimination half-life.
The route did not close because of a rule about peptides.
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
Efficacy was never the question in this appraisal. Duration of treatment was.
A proper account of an operation that existed, and of what closing it cost.